News

Genticel aims to prevent Cancer caused by the Human Papillomavirus


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Genticel aims to prevent Cancer caused by the Human Papillomavirus

 

Date: 03/06/2015


Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002′s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform.

Vaxiclase is a technology platform that can be used with many antigens in several indications. Last February, Genticel signed a first licensing agreement with the Serum Institute of India, the world’s largest producer of vaccine doses, to evaluate Vaxiclase to produce multivalent vaccines against Pertussis, the whooping cough disease. Genticel received up to €51M in upfront and milestones payments, plus royalties on sales.

Schematic diagram of a Vaxiclase-based vaccine. Source: Genticel


For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019